- Home
- PBYI vs SANG Comparison
PBYI vs SANG Comparison
Compare PBYI & SANG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PBYI | SANG |
|---|---|---|
| Founded | 2010 | 1984 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.4M | 170.0M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PBYI | SANG |
|---|---|---|
| Price | $6.10 | $5.03 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 378.0K | 3.4K |
| Earning Date | 11-06-2025 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.87 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | $211,995,000.00 | ★ $227,360,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.59 |
| P/E Ratio | $8.28 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.58 | $4.08 |
| 52 Week High | $6.22 | $7.99 |
Technical Indicators
Market Signals| Indicator | PBYI | SANG |
|---|---|---|
| Relative Strength Index (RSI) | 68.34 | 45.93 |
| Support Level | $5.51 | $4.80 |
| Resistance Level | $5.73 | $5.18 |
| Average True Range (ATR) | 0.23 | 0.13 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 98.31 | 37.40 |
Price Performance
Historical ComparisonAbout PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About SANG Sangoma Technologies Corporation
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.